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The tumor suppressor Wnt inhibitory factor 1
is frequently methylated in nasopharyngeal
and esophageal carcinomas
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Yajun Wang1, Kwan Y Lee1, George SW Tsao4, Sheng Zhong5, Keith D Robertson5, Sun Y Rha6, Anthony TC Chan1
and Qian Tao1,7
Aberrant activation of the wingless-type- (Wnt)-signaling pathway is common in many cancers including nasopharyngeal
(NPC) and esophageal squamous cell (ESCC) carcinomas, both prevalent in Southern China and Southeast Asia. However,
the molecular mechanism leading to this abnormality is still obscure. Wnt inhibitory factor-1 (WIF1) is a secreted an-
tagonist of the Wnt pathway, and is recently shown to be inactivated by epigenetic mechanism in some tumors. Here, we
examined whether WIF1 is also inactivated epigenetically in NPC and ESCC. With semiquantitative reverse transcription-
PCR and methylation-specific PCR, we detected WIF1 downregulation or silencing in 6/6 of NPC and 12/19 of ESCC cell
lines, which is well correlated with its methylation status. Methylation was further confirmed by high-resolution bisulfite
genomic sequencing. Methylation was also frequently observed in a large collection of primary tumors of NPC (85%, 55/
65) and ESCC (27%, 25/92), with WIF1 expressed and unmethylated in normal NPC and esophageal cell lines and normal
tissues. Treatment of 5-aza-20-deoxycytidine demethylated WIF1 and induced its expression in NPC and ESCC cell lines,
highlighting a direct role of epigenetic inactivation. Ectopic expression of WIF1 in NPC and ESCC tumor cells resulted in
significant inhibition of tumor cell colony formation, similar to TP53, and also significant downregulation of b-catenin
protein level in NPC cells. Thus, WIF1 functions as a tumor suppressor for both NPC and ESCC through suppressing the
Wnt-signaling pathway, but is frequently silenced by epigenetic mechanism in a tumor-specific way. Our study indicates
that epigenetic inactivation of WIF1 contributes to the aberrant activation of Wnt pathway and is involved in the
pathogenesis of both tumors. WIF1 methylation could also serve as a specific biomarker for these tumors.
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Wingless-type (Wnt) protein family is a group of secreted
glycoproteins, which plays a pivotal role in regulation of
proliferation and differentiation of epithelial cells.1–3 The
associated canonical Wnt-signaling pathway (known as the
wingless pathway in Drosophila) is the most intensively stu-
died Wnt pathway implicated in oncogenesis. The pathway
involves binding of Wnt ligands to the Frizzled family re-
ceptors at the cell surface which leads to activation of in-
tracellular molecules disheveled. Disheveled in turn inhibits
the glycogen synthase kinase 3b (GSK3b) and allows cyto-
plasmic accumulation of b-catenin.4,5 As a result, b-catenin
translocates into nucleus, interacts with T-cell factor/lym-
phocyte enhancer binding factor,6,7 and activates transcrip-
tion of target oncogenes such as cyclin D1, c-Myc and
VEGF.6,8–11
Two groups of Wnt antagonist with different mechanisms of
action have been identified.12 One group (Dickkopf family)
inhibits the Wnt signaling by binding to the LRP5/LRP6
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subunit of Wnt receptor complex. Wnt inhibitory factor 1
(WIF1) belongs to another group, which acts by direct
binding to Wnt ligands. WIF1 is composed of an N-terminal
signal peptide sequence and 5-epidermal growth factor like
repeats. The WIF1 gene, located at 12q14, was first identified
from human retina.13 It is a highly conserved gene, and does
not share any sequence similarities with the cystine-rich
domains of Frizzled or secreted frizzled-related protein.
There are dense CpG sites in the WIF1 promoter (Figure 1a),
and methylation of these CpG sites leads to the inactivation
of WIF1 in tumors. WIF1 was found to be downregulated by
methylation in various human malignancies including carci-
noma of lungs, mesothelioma, colorectal, various urological
and gastrointestinal malignancies.14–16 We also reported
that WIF1 is frequently inactivated by methylation in breast
cancer.17
Compared with the low incidence in other parts of the
world, nasopharyngeal carcinoma (NPC) and esophageal
squamous cell carcinoma (ESCC) are both prevalent malig-
nancies in Southern Asia including Southern China such as
Hong Kong, with annual incidence reachingB30 andB100/
100 000, respectively. Despite high prevalence of both tumors,
their molecular pathogenesis, especially regarding the epige-
netic aspect, is still poorly known. An increasing amount of
evidence shows that the Wnt/b-catenin pathway is aberrantly
activated in both NPC and ESCC.18,19 However, the detailed
components of Wnt pathway responsible for this aberrant
activation is still to be elucidated. In this study, we examined
the epigenetic alteration and the tumor suppressor function
of WIF1, a recently identified antagonist of the Wnt/b-
catenin pathway, in NPC and ESCC.
MATERIALS AND METHODS
Cell Lines, Tumor Samples and Drug Treatment
A panel of tumor cell lines used, including NPC (C666-1,
CNE1, CNE2, HK1, HNE1 and HONE1), and ESCC (EC1,
Figure 1 (a) Schematic structure of the WIF1 promoter CGI. The exon 1 is indicated with a dark rectangle, CpG sites in the CGI are indicted by short
vertical lines, and the transcription start site indicated by a curved arrow. The MSP and BGS regions analyzed are also indicated. M3 and M4 represent
MSP primers. (b) Broad expression of WIF1 in human normal adult and fetal tissues. (c) Silencing of WIF1 by promoter methylation in NPC and ESCC cell lines,
but not in normal epithelial cell lines. M, methylation; U, unmethylation. (d) Representative MSP results of NPC primary tumors. (e) Representative
MSP results of ESCC primary tumors and paired normal tissues. No methylation was detected in paired normal sample (N) whereas methylation was
frequently observed in ESCC tumors (T). (f) MSP results of NEE, with no methylation detected. M, molecular markers.
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EC18, EC109, HKESC1, HKESC2, HKESC3, SLMT-1,
KYSE30, KYSE70, KYSE140, KYSE150, KYSE180, KYSE270,
KYSE410, KYSE450, KYSE510, KYSE520, KYSE50 and
KYSE220). Three immortalized normal epithelial cell lines,
including one nasopharyngeal (NP69) and two esophageal
(ES) (NE1, NE3) with many features of normal epithelial
cells were also used as controls.20–22 These cell lines were
routinely maintained in RPMI1640 or DMEMmedium. Total
RNA and DNA were extracted from cell pellets or tumor
tissues using TriReagent.23 Source of DNA samples of NPC
and ESCC tumors have been described previously.21–24 Eight
normal esophageal epithelial tissues (NEE) were collected in
the Department of Pathology, University of Hong Kong.25
For drug treatment, cell lines were treated with 5-aza-20-
deoxycytidine (Aza) (Sigma, ST Louis, MO, USA; 50 mM for
NPC cell lines and 10 mM for ESCC cell lines) for 3 days, as
described previously.23
Reverse Transcription-PCR
Semi-quantitative reverse transcription (RT)-PCR was
performed as previously described using Taq-Gold, with
GAPDH as an internal control.23 In brief, RT-PCR was per-
formed by using AmpliTaq Gold (Applied Biosystems, Foster
City, CA, USA), and the PCR programs started with an initial
denaturation at 951C for 10min, followed by 37 cycles (941C
for 30 s, 551C for 30 s and 721C for 30 s) of amplification,
with a final extension at 721C for 10min. PCR bands were
visualized under UV light and photographed. Primers used
were WIF1F: 50-TATGGATCGATGCTCACCAG and WIF1R:
50-CAGAGGGACATTGACGGTTG.
Methylation-Specific PCR and Bisulfite Genomic
Sequencing
Bisulfite modification of DNA was carried out as previously
described.26 In brief, 5mg of genomic DNA was denatured by
adding 3 ml of 3M NaOH at 371C for 15min. Denatured
DNA was mixed with 333 ml of bisulfite solution and in-
cubated in darkness for 4 h at 551C. The bisulfite solution was
prepared as 2.4M sodium metabisulfite (pH 5.0–5.2) (Sig-
ma)/0.5mM hydroquinone. Treated DNA was desalted and
purified using the QIAEX II kit (Qiagen). DNA was then
treated with 0.3M NaOH at 371C for 15min and purified
with QIAEX II. Recovered DNA was eluted in 100 ml of TE
buffer (pH 8.0) and stored at 201C. For methylation-spe-
cific PCR (MSP), bisulfite-modified DNA was amplified
using either a methylation-specific or unmethylation-specific
primer set.27 Methylation-specific primers were WIF1M3:
50-TGTCGTTTTTATTTTCGTTCGC and WIF1M4: 50-CGTT
TAAACGACTAAACGCG, whereas the unmethylation-spe-
cific primers were WIF1U3: 50-TTTTTGTTGTTTTTATTTTT
GTTTGT and WIF1U4: 50-TCCCATTTAAACAACTAAAC
ACA. MSP was performed for 40 (for methylation-specific
primers; 601C) or 42 (for unmethylation-specific primers;
601C) cycles using AmpliTaq Gold and hot-start.27 MSP
primers were tested and confirmed not to amplify any
unbisulfited DNA. For bisulfite genomic sequencing (BGS) to
analyze the methylation status of 46 CpG sites in a 463-bp
region of the WIF1 promoter (402 to þ 61), bisulfite-treated
DNA was amplified using a BGS primer set (WIF1BGS1:
50-GTTTTAGGGGTTTTTGAGTGTT; WIF1BGS2: 50-CAACT
CCCTCAACCAAAACTA), and the PCR products were cloned
into pCR4-Topo vector (Invitrogen, Carlsbad, CA, USA).26
Around eight colonies were randomly chosen and sequenced.
SDS-PAGE and Western Blotting
Anti-a-tubulin (DM1A, Neomarkers), Anti-b-catenin
(M3539, Dako) and HRP-coupled rabbit anti-mouse sec-
ondary antibody (P0161, Dako) were used. Lysates of cells
transfected with pcDNA3.1 or pcDNA3.1-WIF1 were sepa-
rated on 10% Bis/Tris-polyacrylamide gel through electro-
phoresis and blotted onto nitrocellulose membranes
(Amersham). Blots were immunostained with primary anti-
bodies overnight at 41C and secondary antibody for 1 h
at room temperature. Proteins were visualized using ECL
Plus Western blotting Detection Reagents (RPN2132,
GE Healthcare). The film was scanned with a GS-700
Densitometer, and quantitated by Quantity One software
(Bio-Rad).
Colony Formation Assay using Monolayer Culture
The full-length cDNA of WIF1 was PCR cloned, sequence-
verified, and further subcloned into the expression vector
pcDNA3.1() (Invitrogen, Carlsbad, CA, USA) through the
XhoI–HindIII sites. For monolayer culture, freshly seeded
tumor cells (1 105/well) plated in a 12-well plate were
cultured for overnight, then transfected with various expres-
sion plasmids or the empty vector (0.5 mg each) using
FuGENE 6 (Roche).21,22 Cells were plated in a 6-well plate
48 h post-transfection, and selected for 1–2 weeks with G418.
Untransfected cells could not survive with G418 selection and
surviving colonies were stained with Gentian Violet. The
experiments were performed in triplicate wells for three
times. The TP53-expressing plasmid (gift of Dr Bert Vogel-
stein) was used as a positive control.22 The results were
shown as values of mean7s.e. Statistical analysis was carried
out with Student’s t-test, and Po0.05 was considered as
statistically significant difference.
RESULTS
Broad Expression of WIF1 in Normal Tissues but
Frequent WIF1 Silencing by Methylation in NPC and
ESCC Cell Lines
By semiquantitative RT-PCR with GAPDH as a control, the
expression of WIF1 was evaluated in a panel of human
normal tissues and tumor cell lines. WIF1 expression was
readily detectable in all normal adult and fetal tissues, al-
though with varied expression levels (Figure 1b), including
normal upper respiratory tract tissues (larynx, trachea) and
esophagus, which are the normal counterparts for NPC and
esophageal carcinoma. In contrast, WIF1 expression was lost
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or considerably reduced in NPC (6/6, 100%) and ESCC (12/
19, 63%) cell lines (Figure 1c).
To test whether WIF1 silencing is a consequence of epi-
genetic inactivation, the methylation status of the WIF1
promoter was analyzed by both MSP and BGS. For MSP,
methylated alleles were detected in those cell lines with absent
or reduced expression, whereas no methylation was observed
in normal esophageal (NE1, NE3) and nasopharyngeal epi-
thelial cell lines (NP 69) (Figure 1c). Methylation was not
detected in most of the WIF1-expressing cell lines; however,
for some expressing cell lines both methylated and un-
methylated alleles were detected. The MSP results were
confirmed by BGS analyses of a 463-bp region of the WIF1
promoter, which demonstrated densely methylated CpG sites
at the WIF1 promoter in silenced cell lines but not in normal
epithelial cell lines (Figure 2).
Tumor-Specific Methylation of WIF1 in Primary NPC and
ESCC
We further examined WIF1 methylation in a large collection
of primary tumors, some with paired normal tissues. Me-
thylation was observed in 55 of 65 (85%) NPC (Figure 1d)
and 25 of 92 (27%) ESCC tumor samples (Figure 1e). For
ESCC, paired non-tumorous tissues were available for ana-
lysis, of which no methylation was observed in all the 92
samples. Furthermore, all the eight normal esophageal tissue
samples had no methylation at all (Figure 1f). Detailed
methylation analysis using BGS revealed heavily methylated
alleles together with unmethylated alleles (which represent
the tumor-infiltrating normal cells) in primary tumors
(Figure 2). On the other hand, only few methylated CpG sites
were detected in paired normal esophageal tissues (Figure 2).
Pharmacologic Demethylation of the WIF1 Promoter
Restores its Expression in Tumor Cell Lines
Treatment of both NPC and ESCC cell lines with 5-aza-20-
deoxycytidine (Aza) induced demethylation of the WIF1
promoter and its concomitant expression (Figure 3a). Both
MSP and BGS confirmed the demethylation of the promoter
in individual alleles, or at individual CpG sites (Figure 3b).
WIF1 Functions as a Tumor Suppressor through
Downregulating b-Catennin Protein Level
The frequent silencing of WIF1 in both NPC and ESCC but
not normal epithelial tissues or cell lines suggests that WIF1
probably functions as a tumor suppressor in both tumors. To
test this hypothesis, colony formation assay was used to
analyze the tumor suppressor effect of WIF1. We chose
CNE2, HONE1 (NPC cell lines) and EC109 (ESCC cell line)
for transfection owing to their silencing of WIF1 and pro-
moter methylation. The colony formation efficiencies of
these cell lines were significantly suppressed after transfection
with WIF1, comparable to that observed in TP53-transfected
cells (Figure 4a and b), indicating that WIF1 functions as a
tumor suppressor in both NPC and ESCC cells.
Figure 2 Representative high-resolution analyses of the methylation status of individual CpG sites in the WIF1 promoter by BGS in NPC and ESCC cell
lines and primary tumors. Each row indicates a promoter allele analyzed and each circle corresponds to a single CpG site. Methylated sites are indicated
as filled dark circles while unmethylated sites as empty white ones. NP, nasopharyngeal epithelium; ES, esophageal epithelium.
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We further determined the molecular mechanism of this
tumor suppression. As b-catenin is accumulated in both NPC
and ESCC, WIF1 could exert its tumor suppressor functions
through modulating b-catenin level. Thus, intracellular
protein level of b-catenin in HONE1 before and after ectopic
WIF1 expression was determined by Western blot. Indeed,
the intracellular b-catenin protein level was significantly re-
duced after WIF1 expression (Figure 4c). Thus, WIF1 func-
tions as a tumor suppressor in NPC through suppressing the
Wnt-signaling pathway.
DISCUSSION
In the present study, we demonstrated that WIF1 is silenced
by epigenetic mechanism in the majority of cell lines and
large numbers of primary tumors of NPC and ESCC. This is
consistent with studies in other cancer types, which reported
promoter methylation as the major mechanism for in-
activation of this tumor suppressor gene. Furthermore, using
transfection of cell lines with WIF1-expressing plasmid, we
demonstrated that ectopic expression of WIF1 in both NPC
and ESCC cell lines could significantly reduce the colony
formation of tumor cells, highlighting the fact that WIF1 is a
functional tumor suppressor in these two types of tumors.
We also showed evidence that WIF1 exerts its tumor sup-
pressor functions through downregulating intracellular pro-
tein level of b-catenin thus suppressing the Wnt-signaling
pathway.
Cancer development depends on the aberrant deregulation
of signal transduction pathways that control cell growth and
survival. Canonical Wnt signaling pathway is an important
pathway involved in tumor pathogenesis.1 As the initial
report of aberrant activation of Wnt pathway in colorectal
carcinoma, Wnt pathway had been linked up with multiple
other cancer types.7,28 Meanwhile, epigenetic gene silencing is
associated with the onset and progression of various cancers,
and such events can even precede genetic changes during
carcinogenesis.29 Epigenetic modification can be achieved via
either promoter methylation and/or modification of histone
tails in the chromatin. These two epigenetic events are closely
linked and affect each other through interactions between
DNA methyltransferase and histone deacetylase complex
at methylated CpG sites.30,31 Recently, pharmacologic
demethylation has been explored as a cancer therapeutic
strategy through restoring tumor suppressor gene functions
which would induce tumor cell apoptosis or reactivate
silenced viral immunodominant proteins.32,33
NPC is a prevalent tumor in Southern China and South-
east Asia, especially in the 20–44 age group. Despite effective
primary treatment, NPC remains to cause a lot of morbidity
and mortality because of its high propensity of distant meta-
stasis. Although b-catenin was found to be accumulated in
NPC,34 studies on Wnt pathway genes in NPC pathogenesis
are still scanty. In one study with cDNA microarray expres-
sion profiling, the Wnt pathway was found to be deregulated,
whereas its inhibitory molecule AXIN2 was downregulated in
NPC.19 Our results go in line with the above findings and
suggest that epigenetic silencing of another antagonist of the
Wnt pathway, WIF1, contributes to the pathogenesis of NPC.
Previous works from our team had shown that demethylating
agents, azacitidine, can induce in vivo reversal of CpG islands
(CGI) methylation of Epstein–Barr virus (EBV) genes in
NPC.32 Although it is still unclear how significant the role of
WIF1 silencing is in inducing aberrant activation of Wnt
pathway in vivo, in view of its high frequency of epigenetic
Figure 3 (a) Pharmacologic demethylation and reactivation of WIF1 with 5-aza-20-deoxycytidine (Aza) treatment in NPC and ESCC cells.
Semiquantitative RT-PCR analysis detected upregulated expression and MSP detected concomitant demethylation of the promoter in Aza-treated cell
lines. (b) Detailed BGS analysis showed that the percentage of methylated CpG sites was significantly reduced after treatment with Aza.
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inactivation in NPC cell lines and primary tumors, WIF1
could be one of the ideal targets for future development of
epigenetic therapeutics.
ESCC remains to be one of the most lethal gastrointestinal
malignancies in China and other parts of the world. It is well
known that the Wnt pathway is aberrantly activated in ESCC,
although the mechanism of this abnormality is poorly un-
derstood.35,36 In a recent study, WIF1 was found to be si-
lenced epigenetically in a limited number of Japanese ESCC
cell lines and primary tumors.15 We have systematically
analyzed a larger series of ESCC cell lines and a much larger
number of primary tumors from Hong Kong Chinese as well
as paired normal esophageal tissues, NEE tissues and normal
cell lines. The results from these two ethnic groups were si-
milar. We found that WIF1 was only inactivated in ESCC cell
lines and tumors, whereas readily expressed in NEE cell lines.
No methylation of WIF1 was detected in normal esophageal
cell lines and paired normal tissues. We also noticed that in
rare cell lines like EC18, WIF1 expression was low or silent
but without promoter methylation, indicating that other
regulatory mechanism such as histone remodeling is prob-
ably also infrequently involved in silencing WIF1 in tumors.
Although question remains whether accumulation of b-
catenin in cytosol and nucleus would render ESCC patients
poorer prognosis, it had been shown that esophageal tumor
cell growth could be inhibited by downregulation of b-cate-
nin with antisense oligonucleotides.37 It is therefore of
interest to explore further whether demethylation therapy
activating WIF1 will reduce the intracellular b-catenin level
and suppress tumor cell growth.
The Wnt/b-catenin cascade has various components which
ranges from Wnt ligands, Frizzled, disheveled, AXIN/APC/
GSK complexes to b-catenin. One may reasonably wonder
about the significance of those upstream events in affecting
the whole Wnt pathway and the final effector b-catenin. In
one of the report, restoration of WIF1 function induced
significant apoptosis in colorectal cancer cell lines containing
downstream mutations.6 This underscores the therapeutic
value of reversing WIF1 methylation in suppressing the Wnt
cascade despite the presence of downstream mutations, and
indicates a possible Wnt pathway-independent mechanism of
apoptosis induction by WIF1.
The clinical impact of WIF1 inactivation in both NPC and
ESCC is unknown. Further studies of clinical correlation of
WIF1 methylation in a large collection of NPC and ESCC
patients are required to answer this question. It is of interest
to notice that the histology of NPC in Asia is usually
poorly differentiated, whereas ESCC is a more differentiated
Figure 4 Assessing the tumor suppressor function of WIF1 in NPC (HONE1) and ESCC (EC109) cells using colony formation assays (monolayer
culture). (a) Colony formation efficiencies were significantly inhibited in WIF1-expressing cells, which was similar to cells transfected with a TP53-expressing
plasmid, when compared with control cells transfected with vector only. (b) Quantitative analyses of the results in (a). (c) WIF1 functions as a tumor
suppressor through downregulating b-catenin protein level. Intracellular b-catenin level before and after ectopic WIF1 expression was determined by
Western blot with monoclonal anti-b-catenin antibody (upper panel), with a-tubulin as a loading control (middle panel). The signals were further
quantitated (bottom panel).
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squamous cell carcinoma. Previous studies of other tumors
such as prostate, breast and non-small cell lung carcinoma
showed that loss of WIF1 expression was not significantly
associated with tumor stage or grade, suggesting that epige-
netic silencing of WIF1 might be an early event in carcino-
genesis.16 Such characteristics may enable the detection of
WIF1 methylation in NPC or ESCC tumor tissues or serum
samples as a molecular marker for screening and diagnosis.
In conclusion, we have demonstrated that WIF1 is fre-
quently epigenetically inactivated in NPC and ESCC, and
WIF1 also functions as a tumor suppressor in both tumors
through downregulating b-catenin protein level and sup-
pressing the Wnt-signaling pathway.
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